The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Issue 10 (14th October 2021)

• Record Type: Journal Article
• Authors: Masanas, Marc; Masiá, Nuria; Suárez‐Cabrera, Leticia; Olivan, Mireia; Soriano, Aroa; Majem, Blanca; Devis‐Jauregui, Laura; Burgos‐Panadero, Rebeca; Jiménez, Carlos; Rodriguez‐Sodupe, Pau; Boloix, Ariadna; Toledano, Ignasi; Guillén, Gabriela; Navarro, Alexandra; Llobet‐Navas, David; Villanueva, Alberto; Sánchez de Toledo, Josep; Roma, Josep; Noguera, Rosa; Moreno, Lucas; Krauss, Rolf; Gallego, Soledad; Santamaria, Anna; Segura, Miguel F.
• Is Part Of: Clinical and translational medicine. Volume 11:Issue 10(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-14
• Subjects: Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1002/ctm2.533
• Languages: English
• ISSNs: 2001-1326